Ataraxis AI

Big day: Ataraxis raised a $20.4 million Series A from @aixventureshq, @peterthiel, and other top tier VC funds and angel investors, including OpenAI & DeepMind researchers. This funding round comes just a few months after we revealed Ataraxis Breast, the world's first AI-native platform to personalize treatment in breast cancer patients. We also launched Kestrel, our state-of-the-art foundation model for digital pathology. Our frontier AI lab is dedicated to developing and clinically deploying tools that personalize treatment for cancer patients. In October, an 8,000-patient clinical validation study confirmed that Ataraxis Breast accurately identifies high- and low-risk patients, significantly outperforming legacy diagnostic tests. Ataraxis Breast is just the first of many Ataraxis products, and with our Series A financing, we will accelerate their development and deployment to help cancer patients worldwide. Ataraxis is already back to building, and we’re looking for exceptional people to join us. If you're passionate about AI and medicine and want to be a part of the fastest-growing AI precision medicine company, consider joining our team: jobs.ashbyhq.com/ataraxis-ai We are sharing this milestone alongside an exclusive TechCrunch feature. A huge thank you to our employees, investors, patients, and physicians—this journey wouldn’t be possible without you. This is just the beginning.

Today, we’re excited to introduce some of the researchers joining our frontier AI lab, building next-generation models for precision medicine: Cerise Tang, PhD — Research Scientist (prev. Yale postdoc) Alec McClean, PhD — Research Scientist (CMU Stats PhD; prev. NYU Grossman postdoc) Dhruva Biswas, MD, PhD — Translational Science Lead (prev. Yale faculty) Their work will help push the boundaries of what’s possible in applying AI to oncology. We’re still hiring! Learn more at jobs.ataraxis.ai

Today, we’re thrilled to welcome Dr. Jennifer Person, DBA to Ataraxis as our Head of Sales. Jennifer brings 20+ years of commercial leadership in oncology and diagnostics, with a strong track record of building high-performing teams, accelerating adoption, and delivering growth. She joins us from Biotheranostics (a Hologic company), where she held senior sales leadership roles across key accounts and regional leadership. Prior to that, she spent many years at Myriad Genetics, helping scale molecular diagnostics and expand access for patients nationwide. Jennifer will be instrumental as we scale our commercial organization and broaden access to Ataraxis Breast and other AI-native tools for clinicians and patients.

Today we announce a research collaboration between Ataraxis AI and Unicancer to validate the Ataraxis Breast platform using phase III trial data (1,100+ HR+ breast cancer patients). Full release: businesswire.com/news/home/2026…

Ataraxis was featured in podium talks at #SABCS, incl. the Year in Review session on the year’s most impactful breast cancer research. Proud of the clinical relevance & rigor of ATX research—and AI’s growing role in personalizing treatment. Onward to 2026!

Results of this great collaboration between UCLA researchers and Ataraxis AI were presented just last week at the San Antonio Breast Cancer Symposium

Ataraxis AI at #SABCS25: Join us Dec 12 (7:00–8:30 AM CST) for a Poster Spotlight Presentation. We will be sharing international real-world results on Ataraxis Breast RISK—how it reclassifies recurrence risk in HR+/HER2− early breast cancer and compares with the 21-gene assay.

Missing SABCS? Join us Dec 16 at 5 PM EST for the Ataraxis SABCS Research Highlights Webinar. Get key insights from our 8 posters, new real-world Breast RISK data, first Breast NEO results, and updates from our AI lab. Registration Link: go.ataraxis.ai/webinar-sabcs2…

Big news ahead at #SABCS25! We will present eight new studies featuring real-world validation and utility of Ataraxis Breast RISK, head-to-head comparisons with genomic assays, and the first-ever data on Ataraxis Breast NEO, our new test for predicting response to neoadjuvant therapy. We look forward to connecting in San Antonio, December 9–12. Visit us at Booth 1408. Read more: businesswire.com/news/home/2025…

Ataraxis is growing and working on bringing Ataraxis Breast and other AI-native tools to clinicians and patients. Today, we’re introducing some of the outstanding new members who recently joined our commercial and medical teams: - John Benton (Oncology Specialist, prev. Artera) - Mike Rocks (Oncology Specialist, prev. Guardant, Biotheranostics) - Ryan Dunlevy (Oncology Specialist, prev. Hologic, BMS) - Anna Miller (Medical Science Liaison, prev. Caris) This talented group brings deep experience in oncology and diagnostics, and will support clinicians and patients accelerating access to Ataraxis’ solutions. We’re still hiring! Explore opportunities to join our growing team: jobs.ataraxis.ai

Today, we announce a strategic research collaboration between Ataraxis AI and MEDSIR (@wearemedsir), a global leader in oncology research. The partnership will evaluate the Ataraxis Breast platform in several international randomized controlled trials. Together, we aim to generate robust clinical evidence on the role of artificial intelligence in predicting outcomes and treatment effects in early-stage and metastatic breast cancer. The analyses will especially focus on novel therapies investigated in MEDSIR's groundbreaking trials, including CDK4/6 inhibitors and antibody-drug conjugates (ADCs). This is one of many ongoing partnerships at Ataraxis working on developing a robust evidence base supporting the accuracy and utility of Ataraxis AI-native tools, and moving AI precision oncology closer to becoming the standard of care. Read the full announcement here: businesswire.com/news/home/2025…

We are at the TME Fall Summit in New Orleans this week, giving breast surgeons and oncologists one of the first opportunities to learn about how Ataraxis Breast is used in practice. Schedule a call at go.ataraxis.ai/meet-tme25 or learn more at ataraxis.ai/breast

Next week, our CEO @JanWitowski will present the most recent Ataraxis Breast clinical validation results and deployment insights at the 18th International Symposium on Translational Research in Oncology: ccrt.ie/the-18th-inter…

Over the past few months, we’ve doubled the size of our team. Today, we’re excited to introduce some of the researchers joining our frontier AI lab, building next-generation models for precision medicine: - Jeroen Berrevoets (prev. Cambridge Math PhD) - Jungkyu (JP) Park (prev. NYU CS PhD) - Chuwen Liu (prev. Tsinghua Math, UNC Biostats PhD) - Linus Bao (prev. Oxford CS MS) Their work will help push the boundaries of what’s possible in applying AI to oncology. We’re still hiring — learn more at jobs.ataraxis.ai

🏆 Ataraxis won 1st place at the Nebius AI Discovery Awards! Out of 250+ global contenders innovating at the intersection of AI and life sciences, our team was honored to receive the top prize in the biotech category — and a $100,000 award — at the @nebiusai AI Discovery 2025 ceremony today! This recognition as a frontrunner in AI-driven precision medicine is a meaningful milestone, especially as we shared the stage with so many trailblazing startups redefining the future of healthcare. Thank you for this recognition of our work, our Ataraxis Breast AI tests, and Ataraxis research that helps personalize treatment for cancer patients worldwide.

We are at #ASCO25 this weekend! @JanWitowski will be presenting the results from our Ataraxis Breast clinical validation study--stop by to learn how our multi-modal AI and foundation models help personalize breast cancer treatment.

We are hiring for multiple engineering & research roles at Ataraxis AI! We recently raised a $20.4m Series A from top investors (AIX Ventures, Peter Thiel) and are quickly growing to help millions of cancer patients worldwide. Apply now at: jobs.ashbyhq.com/ataraxis-ai